Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 20;9(8):e027168.
doi: 10.1136/bmjopen-2018-027168.

Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial

Zarif K Jabbar-Lopez  1 , Nikeeta Gurung  1 , Danielle Greenblatt  1 , Annette Briley  2 , Joanne R Chalmers  3 , Kim Suzanne Thomas  3 , Tony Frost  4 , Sanja Kezic  5 , John E A Common  6 , Heidi H Kong  7 , Julie A Segre  8 , Simon Danby  9 , Michael J Cork  9 , Janet L Peacock  10 , Carsten Flohr  11
Affiliations

Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial

Zarif K Jabbar-Lopez et al. BMJ Open. .

Abstract

Introduction: Atopic eczema affects 20% of UK children, and environmental factors are important in its aetiology. Several observational studies suggest an increased risk of atopic eczema in children living in hard water areas. The Softened Water for Eczema Prevention pilot trial tests the feasibility of installing domestic ion-exchange water softeners around the time of birth to reduce the risk of atopic eczema in children with a family history of atopy. A further aim is to explore the pathophysiological mechanisms for this in an embedded mechanistic study.

Methods and analysis: Multicentre parallel group assessor-blinded randomised controlled pilot trial. Participants are newborn babies (n=80) living in a hard water (>250 mg/L calcium carbonate) area at risk of developing atopic eczema because of a family history of atopy. Participants will be randomised prior to birth in a 1:1 ratio. The intervention group will have an ion-exchange water softener installed prior to birth. The control group will receive their usual domestic hard water supply. Follow-up will be until 6 months of age. Data will be collected at birth (baseline), 1, 3 and 6 months of age. The main outcome is the proportion of eligible families screened who are willing and able to be randomised. Several secondary feasibility and clinical endpoints will also be evaluated, alongside mechanistic outcomes. Data will be analysed on an intention-to-treat basis. There will be no hypothesis testing for the clinical outcomes. Study acceptability will be evaluated through semistructured interviews.

Ethics and dissemination: This study has been reviewed and given a favourable opinion by the North West-Liverpool East Research Ethics Committee (Ref: 17/NW/0661). The results of the study will be reported at international conferences and in peer-reviewed scientific journals. We will send participating families a summary of the pilot trial results.

Trial registration number: NCT03270566.

Keywords: atopic eczema; dermatology; pilot trial; water hardness.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CF has received investigator-led research funding from Sanofi. His department has received clinical trial funding from Sanofi and AbbVie to test novel therapeutics in patients with paediatric atopic eczema. MJC is an investigator and consultant for Regeneron, Sanofi Genzyme, Pfizer, Leo, Galapagos, Novartis, Boots, L’Oreal, Dermavant, Menlo, Reckitt Benckiser, Oxagen, Johnson & Johnson, Hyphens, Astellas, Amlar, AbbVie, Galderma and Procter & Gamble. Harvey Water Softeners (HWS) contributed to the design and operational running of the study (supply and installation of water softeners, testing of water samples). Final decisions around design and conduct were made independently by investigators. HWS will not be involved in the analysis or interpretation of the results.

Figures

Figure 1
Figure 1
Study flow chart.
See this image and copyright information in PMC

References

    1. Williams H, Robertson C, Stewart A, et al. . Worldwide variations in the prevalence of symptoms of atopic eczema in the International study of asthma and allergies in childhood. J Allergy Clin Immunol 1999;103:125–38. 10.1016/S0091-6749(99)70536-1 - DOI - PubMed
    1. Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy 2014;69:3–16. 10.1111/all.12270 - DOI - PubMed
    1. Weidinger S, Novak N, dermatitis A. Atopic dermatitis. Lancet 2016;387:1109–22. 10.1016/S0140-6736(15)00149-X - DOI - PubMed
    1. Flohr C, Mann J. New approaches to the prevention of childhood atopic dermatitis. Allergy 2014;69:56–61. 10.1111/all.12343 - DOI - PubMed
    1. McNally NJ, Williams HC, Phillips DR, et al. . Atopic eczema and domestic water hardness. Lancet 1998;352:527–31. 10.1016/S0140-6736(98)01402-0 - DOI - PubMed

Publication types

Associated data